Search results for "Leukotriene Antagonists"

showing 10 items of 11 documents

15(S)-HETE modulates LTB(4) production and neutrophil chemotaxis in chronic bronchitis.

2000

We evaluated the levels of 15(S)-hydroxyeicosatetraenoic acid [15(S)-HETE] and the expression of 15-lipoxygenase (15-LO) mRNA in induced sputum obtained from 10 control and 15 chronic bronchitis subjects. 15(S)-HETE was evaluated by reverse phase high-performance liquid chromatography separation followed by specific RIA. 15-LO mRNA expression was determined by primed in situ labeling. The levels of both soluble and cell-associated 15(S)-HETE resulted significantly higher in chronic bronchitis than in control subjects. The percentage of cells expressing 15-LO mRNA was significantly higher in chronic bronchitis than in control subjects ( P < 0.01). Double staining for specific cell type ma…

AdultChronic bronchitisPhysiologyLeukotriene B4Cell SurvivalNeutrophilsNeutrophileCell CountLeukotriene B4chemistry.chemical_compoundHydroxyeicosatetraenoic AcidsMedicineArachidonate 15-LipoxygenaseHumansLung Diseases ObstructiveRNA MessengerBronchitisCells CulturedIn Situ HybridizationAgedbiologyIonophoresbusiness.industryMacrophagesSputumChemotaxisCell BiologyMiddle Agedmedicine.diseaseImmunohistochemistryChemotaxis Leukocytemedicine.anatomical_structureEicosanoidchemistryArachidonate 5-lipoxygenaseImmunologyChronic Diseasebiology.proteinBronchitisLeukotriene AntagonistsbusinessRespiratory tractAmerican journal of physiology. Cell physiology
researchProduct

Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cet…

2001

Background The cause and pathogenesis of chronic urticaria are still poorly understood. IgE-independent reactions, are common in adult patients with chronic urticaria, who have daily spontaneous occurrence of weals. H1-receptor antagonists (antihistamines) are the major class of therapeutic agents used in the management of urticaria and angioedema. Nevertheless, chronic urticaria is often difficult to treat and may not be controlled by antihistamines alone. It has been postulated that mediators other than histamine, such as kinins, prostaglandin and leukotrienes, may be responsible for some of the symptoms in urticaria which are not controlled by antihistamines. In this study, which was ran…

AdultCyclopropanesMalemedicine.medical_specialtyAdolescentUrticariaImmunologyAcetatesSulfidesPlaceboGastroenterologyDouble-Blind Methodimmune system diseasesInternal medicinemedicineImmunology and AllergyHumansskin and connective tissue diseasesAdverse effectMontelukastAgedLeukotrieneAngioedemaAspirinLeukotriene receptorbusiness.industryIncidenceMiddle Agedmedicine.diseaseCetirizineCetirizineFood intoleranceTreatment OutcomeItalyImmunologyChronic DiseaseHistamine H1 AntagonistsQuinolinesLeukotriene AntagonistsFemaleFood AdditivesSleep Stagesmedicine.symptombusinessFood Hypersensitivitymedicine.drugClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
researchProduct

Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for…

2004

BACKGROUND: H 1 -receptor antagonists are considered to be particularly effective in reducing pruritus, and they are therefore recommended as first-line treatment in patients with chronic idiopathic urticaria (CIU). Recently, antileukotriene receptors have been used in patients with CIU, either administered as monotherapy or combined with H 1 -receptor antagonists. OBJECTIVE: We compared the clinical efficacy of 5 mg of desloratadine administered once daily either as monotherapy or combined with a leukotriene antagonist, 10 mg of montelukast daily, and 10 mg of montelukast administered daily as monotherapy for the treatment of patients affected by CIU with placebo. METHODS: One hundred sixt…

AdultCyclopropanesMalemedicine.medical_specialtyHistamine H1 Antagonists Non-SedatingSettore MED/09 - Medicina InternaAdolescentUrticariamedicine.medical_treatmentImmunologyPlacebo-controlled studyRandomized placebo-controlled trial; desloratadine; montelukast; chronic idiopathic urticariaAcetatesSulfidesPlaceboGastroenterologylaw.inventionchemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineImmunology and AllergyHumansMontelukastAgedDesloratadineLeukotriene E4Leukotriene receptorbusiness.industrydesloratadineRandomized placebo-controlled trialLoratadineMiddle AgedAntileukotrieneTreatment OutcomechemistryAnesthesiachronic idiopathic urticariaChronic DiseasemontelukastQuinolinesLeukotriene AntagonistsFemalebusinessmedicine.drug
researchProduct

“Cysteinyl leukotriene-1 receptor activation in a human bronchial epithelial cell line leads to signal transducer and activator of transcription 1-me…

2008

Abstract We studied the effect of leukotriene D(4) (LTD(4)) on a human bronchial epithelial cell line (16HBE) overexpressing the cysteinyl leukotriene (CysLT) (1) receptor (HBECysLT(1)R), looking at the associated signal transduction mechanisms as well as at effects on inflammatory cell adhesion. The results obtained showed that LTD(4) increases the phosphorylation of extracellular signal-regulated protein kinase (ERK) 1/2 and of the signal transducer and activator of transcription 1 (STAT-1) in serine 727 (STAT-1Ser727), resulting in increased eosinophil adhesion to HBECysLT(1)R, associated with enhanced surface expression of intercellular adhesion molecule (ICAM) 1. Pretreatment with a Cy…

CyclopropanesMAPK/ERK pathwayIndolesBronchiAcetatesSulfidesBiologyCysteinyl leukotriene-1cysteinyl leukotrieneCell LineLeukotriene D4MaleimidesInterferon-gammaCell AdhesionHumansProtein kinase ACells CulturedProtein kinase CReceptors LeukotrienePharmacologyKinaseMEK inhibitorMembrane ProteinsEpithelial CellsIntercellular Adhesion Molecule-1Intercellular adhesion moleculeCell biologyEosinophilsSTAT1 Transcription FactorQuinolinesLeukotriene AntagonistsMolecular MedicinePhosphorylationMitogen-Activated Protein KinasesSignal transduction
researchProduct

Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus monteluk…

2004

BACKGROUND: Corticosteroids are considered to be particularly effective in reducing nasal congestion and are therefore recommended as first-line treatment in allergic rhinitis patients with moderate to severe and/or persistent symptoms. OBJECTIVE: We compared the clinical efficacy of fluticasone propionate aqueous nasal spray (FPANS) 200 microg given once daily, administered in mono-therapy or combined therapy with a H1 receptor antagonist (cetirizine, CTZ) or with a leukotriene antagonist (montelukast, MSK), and the combined therapy of CTZ plus MSK in the treatment of patients affected by allergic rhinitis to Parietaria during natural pollen exposure. In addition, we examined the effect of…

CyclopropanesMaleAllergySettore MED/09 - Medicina Internamedicine.medical_treatmentseasonal allergic rhinitisAcetatesGastroenterologyImmunology and AllergyMedicineChildFluticasonepollen seasonRandomized placebo-controlled trialBlood Proteinsrespiratory systemEosinophil Granule ProteinsMiddle AgedCetirizineAnesthesiamontelukastHistamine H1 AntagonistsQuinolineseosinophil cationic proteinDrug Therapy CombinationFemaleeosinophilsmedicine.symptommedicine.drugAdultmedicine.medical_specialtyAdolescentImmunologyNasal congestionSulfidesPlaceboFluticasone propionateDrug Administration ScheduleRibonucleasesDouble-Blind MethodInternal medicineHumansRandomized placebo-controlled trial; fluticasone; cetirizine; montelukast; seasonal allergic rhinitisGlucocorticoidsMontelukastAdministration IntranasalAnalysis of Variancerhinorrheafluticasone propionatebusiness.industrynasal lavageRhinitis Allergic Seasonalmedicine.diseaseCetirizineAndrostadienesParietariaNasal sprayFluticasoneLeukotriene AntagonistsNasal administrationbusinessClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
researchProduct

Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients

2013

Asthma is a disease of all ages. This assumption has been challenged in the past, because of several cultural and scientific biases. A large body of evidence has accumulated in recent years to confirm that the prevalence of asthma in the most advanced ages is similar to that in younger ages. Asthma in the elderly may show similar functional and clinical characteristics to that occurring in young adults, although the frequent coexistence of comorbid conditions in older patients, together with age-associated changes in the human lung, may lead to more severe forms of the disease. Management of asthma in the elderly follows specific guidelines that apply to all ages, although most behaviors ar…

CyclopropanesMalePediatricsmedicine.medical_specialtyQuinolineDiseaseReviewSettore MED/10 - Malattie Dell'Apparato Respiratorioairway inflammationAcetatesSulfidesAnti-asthmatic AgentMaintenance therapyleukotriene antagonistmedicineAnti-Asthmatic AgentHumansAnti-Asthmatic AgentsYoung adultMontelukastAsthmaAgedAged 80 and overLeukotrienetreatmentAcetatebusiness.industryagingGeneral MedicineasthmaMiddle Agedmedicine.diseaseClinical trialleukotriene antagonistsPhysical therapyQuinolinesFemaleGeriatrics and GerontologybusinessHumanmedicine.drugClinical Interventions in Aging
researchProduct

Anti-inflammatory medications for the treatment of pediatric obstructive sleep apnea

2020

CyclopropanesPulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentmedicine.drug_classAnti-Inflammatory AgentsAdministration OralAcetatesSulfidesAnti-inflammatorylaw.inventionRandomized controlled trialAdrenal Cortex HormoneslawInternal medicinemedicineHumansChildAdministration IntranasalMontelukastSleep Apnea Obstructivebusiness.industryInfantmedicine.diseaseObstructive sleep apneaTreatment OutcomeChild PreschoolPediatrics Perinatology and Child HealthQuinolinesLeukotriene Antagonistsbusinessmedicine.drugPaediatric Respiratory Reviews
researchProduct

Effects of inhaled corticosteroids, leukotriene receptor antagonists, or both, plus long-acting beta2-agonists on asthma pathophysiology: a review of…

2004

Chronic inflammation and smooth muscle dysfunction are consistent features of asthma, and are responsible for disease progression and airway remodelling. The development of chronic airway inflammation depends upon the recruitment and activation of inflammatory cells and the subsequent release of inflammatory mediators, including cytokines. Cellular and histological evaluation of drugs with anti-inflammatory activity, such as inhaled corticosteroids (ICSs), is achieved by analysing samples of lung tissue or biological fluids, obtained by techniques such as bronchial biopsy, bronchoalveolar lavage and sputum induction. These provide valuable information on the inflammatory processes occurring…

Pathophysiology of asthmamedicine.drug_classInflammationAdrenal Cortex HormonesBronchodilatorAdministration InhalationmedicineHumansPharmacology (medical)Adrenergic beta-2 Receptor AgonistsAsthmaLungmedicine.diagnostic_testLeukotriene receptorbusiness.industryNebulizers and Vaporizersmedicine.diseaseAsthmarespiratory tract diseasesmedicine.anatomical_structureBronchoalveolar lavageDelayed-Action PreparationsImmunologyLeukotriene AntagonistsBronchoconstrictionDrug Therapy CombinationReceptors Adrenergic beta-2medicine.symptombusinessDrugs
researchProduct

Current and future pharmacologic therapy of exacerbations in chronic obstructive pulmonary disease and asthma.

2005

Exacerbations are an important cause of the morbidity and mortality associated with asthma and chronic obstructive pulmonary disease. Newer therapies include long-acting beta(2)-agonists, which are more effective than short-acting bronchodilators. Inhaled corticosteroids and, in asthma, leukotriene receptor antagonists may have roles in the early phase of exacerbation as an alternative to or added to oral prednisolone. In the future, combinations of long-acting beta(2)-agonists and anticholinergic bronchodilators may offer additive clinical benefits. However, although the treatment and prevention of exacerbations of chronic obstructive pulmonary disease and asthma have been improved by usin…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyExacerbationPulmonary diseaseInhaled corticosteroidsPulmonary Disease Chronic ObstructivePharmacotherapyAdrenal Cortex HormonesmedicineHumansPharmacologic therapyAnti-Asthmatic AgentsIntensive care medicineAsthmabusiness.industryAdrenergic beta-Agonistsmedicine.diseaseAsthmaAnti-Bacterial AgentsBronchodilator AgentsDrug CombinationsEtiologyDisease ProgressionLeukotriene AntagonistsDrug Therapy CombinationEarly phasebusinessForecastingProceedings of the American Thoracic Society
researchProduct

Is there a role for antileukotrienes in urticaria?

2006

In vitro and in vivo clinical and experimental data have suggested that leukotrienes play a key role in inflammatory reactions of the skin. Antileukotriene drugs, i.e. leukotriene receptor antagonists and synthesis inhibitors, are a new class of anti-inflammatory drugs that have shown clinical efficacy in the management of asthma. We searched the MedLine database and carried out a manual search on journals specializing in allergy and dermatology for the use of antileukotriene drugs in urticaria. Montelukast might be effective in chronic urticaria associated with aspirin or food additive hypersensitivity or with autoreactivity to intradermal serum injection when taken with an antihistamine b…

medicine.medical_specialtyAllergyLeukotrienesSettore MED/09 - Medicina InternaUrticariamedicine.medical_treatmentDermatologyCold urticariaimmune system diseasesparasitic diseasesmedicineHumansZafirlukastskin and connective tissue diseasesMontelukastAsthmaClinical Trials as TopicAspirinbusiness.industryAnti-Inflammatory Agents Non-SteroidalZileutonmedicine.diseaseDermatologyAntileukotrieneantileukotrieneantileukotrienes; urticariaHistamine H1 AntagonistsLeukotriene AntagonistsAntihistamineDrug Therapy CombinationFood Additivesbusinessmedicine.drugClinical and experimental dermatology
researchProduct